

Cancer Biology

ISSN: 2150-1041 (print); ISSN: 2150-105X (online); doi:10.7537/j.issn.2150-1041; Quarterly
<http://www.cancerbio.net>

CANCER BIOLOGY is a journal that considers full-length articles and Mini Reviews in a broad range of cancer research, from those elucidating advances in understanding the disease processes of cancer to those helping to establish new paradigms in the diagnosis, treatment, and prevention of cancers. Examples of areas covered by Cancer Biology are: Molecular and cellular mechanisms of cancer biology, such as apoptosis, cell cycle/checkpoint regulation, the genetics and epigenetics of tumorigenesis, angiogenesis and lymphangiogenesis, invasion, metastasis, and host immune responses to cancer. Experimental therapeutics for cancers, including the elucidation of mechanisms for the sensitivity and the resistance to current cancer therapies, identification of new therapeutic targets, and development of new cancer therapies.

Editor-in-Chief: Ma, Hongbao, Ph.D., Professor

Associate Editor-in-Chief: Huang, Wenlin, Ph.D., Professor

Editorial Board

Name	Department
Baylin, Stephen B.	Johns Hopkins University School of Medicine, USA
Cao, Xuetao	Second Military Medical University, China
Cao, Yihai	Microbiology and Tumorbiology Center, Karolinska Institutet, China
Chen, Guoqiang	Shanghai Jiao Tong University, China
Croce, Carlo M.	Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Evnberg, Ingermar	Microbiology and Tumor Biology Center, Karolinska Institute, Sweden
Gao, George Fu	Institute of Microbiology Chinese Academy of Sciences, China
Gottlieb, Eyal	Beatson Institute for Cancer Research, Glasgow, United Kingdom
Guan, Zhongzhen	Cancer Center, Sun Yat-Sen University, China
Hamada, Katsuyuki	Kobe University, Japan
Hao, Xishan	Tianjin Cancer Hospital, China
He, Jie	Cancer Institute and Hospital, Chinese Academy of Medical Sciences, China
Huang, Wenlin	Cancer Center, Sun Yat-Sen University, China
Levine, Arnold J.	Institute for Advanced Study School of Natural Sciences Einstein Drive, Princeton, USA
Lowe, Scott W.	Cold Spring Harbor Laboratory, Cold Spring Harbor, USA
Lung, Maria	Department of Biology, The Hong Kong University of Science & Technology, China.
Ma, Hongbao	Brookdale University Hospital and Medical Center, USA
Mak, Tak W.	Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital Toronto, CA.
Massague, Joan	Memorial Sloan-Kettering Cancer Center, New York, USA
Masucci, Maria	Dept of Cell and Molecular Biology, Karolinska Institute, Sweden
Shao, Jianyong	Cancer Center, Sun Yat-Sen University, China
Shirakawa, Toshiro	Ehime University, Japan
Song, Erwei	Sun Yat-sen Memorial Hospital, China
Su, Yiren	National Cheng Kung University Medical College, China
Sun, Yan	Cancer Institute and Hospital, Chinese Academy of Medical Sciences, China
Tao, Qian	The Chinese University of Hong Kong, China
Wei, Yuquan	West China Hospital, Sichuan University, China

Weinberg, Robert A.	Daniel K. Ludwig and American Cancer Society for Cancer Research, USA
Wu, Zuze	Academy of Military Medical Sciences, China
Yang, Huanming	Beijing Genomics Institute, Chinese Academy of Science, China
Yin, Yuxin	Peking University, China
Zaki, Mona S.	Department of Hydrobiology, National Research Centre, Egypt
Zeng, Yixin	Cancer Center, Sun Yat-Sen University, China
Zheng, Shusen	The First Affiliated Hospital of College of Medicine, Zhejiang University, China

GUIDELINE FOR AUTHORS

CANCER BIOLOGY is a journal that considers full-length articles and Mini Reviews in a broad range of cancer research, from those elucidating advances in understanding the disease processes of cancer to those helping to establish new paradigms in the diagnosis, treatment, and prevention of cancers. Examples of areas covered by *Cancer Biology* are: Molecular and cellular mechanisms of cancer biology, such as apoptosis, cell cycle/checkpoint regulation, the genetics and epigenetics of tumorigenesis, angiogenesis and lymphangiogenesis, invasion, metastasis, and host immune responses to cancer; Experimental therapeutics for cancers, including the elucidation of mechanisms for the sensitivity and the resistance to current cancer therapies, identification of new therapeutic targets, and development of new cancer therapies; Identification of new markers for classification, diagnosis, or prognosis of cancers, or for prediction of response to treatments with clinical significance. Development and analysis of tumor models that enhance our understanding of human tumor development and/or that improve preclinical testing of diagnostic, treatment and prevention strategies for cancer patients. The columns in the issues of *Cancer Biology*(CB) will include: (1) Editorial: To introduce and comment on the substantial advance and its importance in the fast-developing areas; (2) Frontier: To review the most representative achievements and comment on the current research status in the important fields, and propose directions for the future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Basic Research: To provide Guidelines for basic research; (6) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (7) Review: To systemically review the most representative progress and unsolved problems in the major scientific disciplines, comment on the current research status, and make suggestions on the future work; (8) Original Article: To originally report the innovative and valuable findings in cancer biology; (9) Brief Article: To briefly report the novel and innovative findings; (10) Case Report: To report a rare or typical case; (11) Letters to the Editor: To discuss and make reply to the contributions published in

CB, or to introduce and comment on a controversial issue of general interest; (12) Book Reviews: To introduce and comment on quality monographs of cancer biology.

SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1 line spacing and 10 pt. Number all pages consecutively, and start each of the following sections on a new page: Title, Authors, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the International Committee of Medical Journal Editors to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly accessible registry at its outset (<http://www.clinicaltrials.gov>, sponsored by the United States National Library of Medicine, and we encourage all potential contributors to register with it). A letter of recommendation from each author's organization is preferred be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Online submissions: Manuscripts should be submitted through the email editor@sciencepub.net or sciencepub23@gmail.com.

MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1 line spacing and 10 pt. Style should conform to our house format: <http://www.sciencepub.net/marslandfile/template>. Required information for each of the manuscript sections is as follows:

Title: Full title must be in top.

Authorship: Authorship credit should be in accordance with the standard proposed by International Committee of Medical Journal Editors, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version

to be published. Authors should meet conditions 1, 2, and 3.

Institution: Author names should be given first, then the complete name of institution, city, province and postcode.

Author contributions: The format of this section should be: Author contributions: Wang ZL and Lin Q contributed equally to this work; Wang ZL Lin Q and Zeng TC designed the research; Zhong CR, performed the research; Zeng TC analyzed the data; and Gong L and Xu JM wrote the paper.

Email(s): At least one email address must be offered.

Supportive foundations: The complete name and number of supportive foundations should be provided, e.g., Supported by National Natural Science Foundation of China, No. 65651271.

Correspondence to: Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email.

Telephone and fax: Telephone and fax should consist of +, country number, district number and telephone or fax number.

Peer reviewers: All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *CB*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article.

Abstract: An informative, structured abstracts should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/...; MATERIALS AND METHODS (no more than 150 words); RESULTS (no more than 250 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained; CONCLUSION.

Key words: Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

Text: For articles of these sections, original articles, rapid communication and case reports, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both.

Illustrations: Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects.

Tables: Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

Notes in tables and illustrations: Data that are not statistically significant should not be noted. $aP < 0.05$, $bP < 0.01$ should be noted ($P > 0.05$ should not be noted). If there are other series of *P* values, $cP < 0.05$ and $dP < 0.01$ are used. A third series of *P* values can be expressed as $eP < 0.05$ and $fP < 0.01$. Other notes in tables or under illustrations should be expressed as 1F, 2F, 3F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a certain sequence.

Acknowledgments: Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

References: Please follow the template: <http://www.sciencepub.net/marslandfile/template>.

Publication fee: US\$100/paper.

RESUBMISSION OF THE REVISED MANUSCRIPTS

Please revise your article according to the revision policies of *Cancer Biology*. The revised version includes manuscript and high-resolution image figures. The author should re-submit the revised/formatted manuscript online, along with copyright transfer letter, and responses to the reviewers to us *via* email. The template is available at: <http://www.sciencepub.net/marslandfile/template>.

Marsland Press, PO Box 180432, Richmond Hill, Queens, New York 11418, USA, 347-321-7172
editor@sciencepub.net; <http://www.cancerbio.net>

© 2011-2015 Marsland Press